Glaxosmithkline Plc Stock Fundamentals
| GSKN Stock | MXN 739.40 0.57 0.08% |
GlaxoSmithKline plc fundamentals help investors to digest information that contributes to GlaxoSmithKline Plc's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline Plc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline Plc stock.
GlaxoSmithKline |
GlaxoSmithKline plc Company Profit Margin Analysis
GlaxoSmithKline Plc's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current GlaxoSmithKline Plc Profit Margin | 0.51 % |
Most of GlaxoSmithKline Plc's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, GlaxoSmithKline plc has a Profit Margin of 0.51%. This is 104.55% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The profit margin for all Mexico stocks is 140.16% lower than that of the firm.
GlaxoSmithKline plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GlaxoSmithKline Plc's current stock value. Our valuation model uses many indicators to compare GlaxoSmithKline Plc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlaxoSmithKline Plc competition to find correlations between indicators driving GlaxoSmithKline Plc's intrinsic value. More Info.GlaxoSmithKline plc is rated # 2 in return on equity category among its peers. It also is rated # 2 in return on asset category among its peers reporting about 0.21 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for GlaxoSmithKline plc is roughly 4.75 . Comparative valuation analysis is a catch-all model that can be used if you cannot value GlaxoSmithKline Plc by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GlaxoSmithKline Plc's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.GlaxoSmithKline Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline Plc's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline Plc could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline Plc by comparing valuation metrics of similar companies.GlaxoSmithKline Plc is currently under evaluation in profit margin category among its peers.
GlaxoSmithKline Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.79 T | |||
| Shares Outstanding | 2.05 B | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 14.10 % | |||
| Price To Earning | 11.33 X | |||
| Price To Book | 6.05 X | |||
| Price To Sales | 37.65 X | |||
| Revenue | 29.32 B | |||
| Gross Profit | 19.92 B | |||
| EBITDA | 8.8 B | |||
| Net Income | 14.96 B | |||
| Cash And Equivalents | 6.53 B | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 19.76 B | |||
| Debt To Equity | 0.98 % | |||
| Current Ratio | 1.43 X | |||
| Book Value Per Share | 5.25 X | |||
| Cash Flow From Operations | 7.4 B | |||
| Earnings Per Share | 49.71 X | |||
| Price To Earnings To Growth | 1.04 X | |||
| Number Of Employees | 45 | |||
| Beta | 0.28 | |||
| Market Capitalization | 1.38 T | |||
| Total Asset | 60.15 B | |||
| Retained Earnings | (3.7 B) | |||
| Working Capital | 1.91 B | |||
| Current Asset | 15.83 B | |||
| Current Liabilities | 13.92 B | |||
| Z Score | 41.4 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 5.28 % | |||
| Net Asset | 60.15 B | |||
| Last Dividend Paid | 0.61 |
About GlaxoSmithKline Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GLAXOSMITHKLINE is traded on Mexico Stock Exchange in Mexico.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GlaxoSmithKline Stock Analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.